6:20 PM
 | 
Dec 06, 2012
 |  BC Extra  |  Company News

CIRM: GSK drops plans to co-develop ViaCyte program

The California Institute for Regenerative Medicine disclosed in a memo for an upcoming meeting of the institute's governing board that GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) was "not able to obtain the final approval" to help develop a diabetes program from ViaCyte Inc. (San Diego, Calif.). At an October...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >